BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Bipolar disorder clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for bipolar disorder: 35 (24 sponsors; 2 newly posted in the last 180 days, 2 stopped in the last 180 days; 2 new-entrant sponsors). Momentum score 15.7, rank 40 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 0, Phase 1 3, Phase 2 9, Phase 3 11, Phase 4 2, N/A 10.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Bristol-Myers Squibb BMY | 4 | P3 4 | 0 | 0 |
| Alkermes, Inc. ALKS | 2 | P3 2 | 0 | 0 |
| Intra-Cellular Therapies, Inc. | 2 | P3 2 | 0 | 0 |
| Xenon Pharmaceuticals Inc. XENE | 2 | P3 2 | 0 | 0 |
| AbbVie ABBV | 4 | P2 2, P1 1, P3 1 | 0 | 3 |
| Neurocrine Biosciences NBIX | 2 | P2 1, P4 1 | 0 | 0 |
| Psyrin Inc. | 2 | NA 2 | 0 | 0 |
| Akrivia Health | 1 | NA 1 | 0 | 0 |
| Alcediag | 1 | NA 1 | 0 | 0 |
| Alto Neuroscience ANRO | 1 | P2 1 | 0 | 0 |
| Alzamend Neuro, Inc. ALZN | 1 | P2 1 | 0 | 0 |
| Autobahn Therapeutics, Inc. | 1 | P2 1 | 0 | 0 |
| BioXcel Therapeutics Inc BTAIQ | 1 | P1 1 | 0 | 0 |
| Boryung Pharmaceutical Co., Ltd | 1 | NA 1 | 0 | 0 |
| Bosnalijek D.D new entrant | 1 | NA 1 | 1 | 1 |
| diaMentis Inc. | 1 | NA 1 | 0 | 1 |
| Eli Lilly and Company LLY | 1 | P2 1 | 0 | 0 |
| Gaize | 1 | NA 1 | 0 | 0 |
| LB Pharmaceuticals Inc. LBRX | 1 | P2 1 | 0 | 0 |
| Mapi Pharma Ltd. | 1 | P2 1 | 0 | 1 |
| Neurelis, Inc. new entrant | 1 | P1 1 | 1 | 1 |
| Vanda Pharmaceuticals VNDA | 1 | P4 1 | 0 | 0 |
| Vielight Inc. | 1 | NA 1 | 0 | 0 |
| Zimmer Biomet ZBH | 1 | NA 1 | 0 | 1 |
New-entrant sponsors: Bosnalijek D.D, Neurelis, Inc..
Recently stopped trials
- NCT03513549 Nova Pneuma Inc. - suspended: Low commercial usage of ADASUVE resulting in low patient enrollment. NPI has placed this study on hold until market uptake increases and mak Observational Study Evaluating the Safety of ADASUVEĀ® in Agitation Associated With Schizophrenia or Bipolar I Disorder
- NCT07329673 Qbtech AB - suspended: Enrollment/study activities have been temporarily suspended while the sponsor evaluates internal study priorities and resource allocation. T An Examination of the Performance of QbMobile in Differential Diagnosis Associated With ADHD Symptoms
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-31 est. | P1/P2 | Mapi Pharma Ltd. | NCT07185815 Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatmen | Schizophrenia; Bipolar I Disorder; Major Depressive Disorder | recruiting | 24 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-02 est. | P3 | Bristol-Myers Squibb BMY | NCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2) | Bipolar Disorder Type I With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-11-01 est. | P3 | Bristol-Myers Squibb BMY | NCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder | Bipolar-I Disorder With Mania or Mania With Mixed Features | recruiting | 274 |
| 2026-09 est. | P3 | Alkermes, Inc. ALKS | NCT05303064 Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | Schizophrenia; Bipolar I Disorder | recruiting | 220 |
| 2026-08-05 | P2 | Rapport Therapeutics Inc. RAPP | NCT07046494 Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder | Bipolar 1 Disorder | completed | 253 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "bipolar disorder"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.